spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Avacta and Mologic Enter Research and Product Development Collaboration Agreement

Avacta Analytical

Biotherapeutics developer and diagnostic development company join forces in R&D

  • Avacta’s Affimer technology will be used to develop rapid lateral flow diagnostics for clinical applications
  • Development and commercialisation partnership in point of care testing
  • Lateral flow diagnostics market is worth $5bn annually and is growing at around 7% per annum
Wetherby and Cambridge, UK, 13 June 2016: Avacta Group plc (AIM: AVCT) (“Avacta” or “the Group”) the developer of Affimer® biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, today announced they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point of care (POC) testing, using Avacta’s Affimer technology. As stated at the time of Avacta’s interim results, establishing commercial relationships in the POC testing market is one of the Company’s key strategic objectives.

The non-exclusive collaboration with Mologic will focus on the development of novel Affimer-based diagnostic assays and the subsequent development of new lateral flow devices (LFDs) as POC diagnostics for human healthcare. Both companies will share in the future revenues from the commercialisation of the marketed diagnostics.

POC testing is performed at the time and place of patient care (e.g. doctor’s surgery), and provides results more rapidly than if samples are sent to a laboratory. POC testing is dominated by lateral flow technology where the test result is displayed through the appearance of coloured bars on a test strip. The lateral flow diagnostics market is worth $5bn annually and is growing at around 7% per annum.

The development of Affimer-based LFDs will address many of the existing limitations of traditional antibody-based systems. Current lateral flow technology relies predominantly on antibody-based detection which can limit specificity and the detection of certain classes of target molecule. In addition, lengthy development times, combined with poor consistency and reproducibility often create manufacturing challenges. In comparison, the generation of Affimer molecules typically takes weeks rather than months, and as the process is based on tuneable, recombinant technology, Affimer reagents can be specifically engineered to a wide range of targets, in a highly consistent, reproducible and cost-effective process.

Mologic, whose senior management team has a long track record of successfully bringing rapid tests to market, is a UK-based developer of POC solutions and has been developing lateral flow technology for well over a decade.

Dr Alastair Smith, Chief Executive Officer, Avacta, commented: “I am very pleased that we have established this collaborative partnership with Mologic, who are well recognised as an innovative developer of lateral flow devices. It is important that Avacta forges co-development relationships such as this in the strategic application areas we have identified. They offer the opportunity to leverage each party’s expertise to rapidly progress and develop the Affimer technology in these key markets, for delivery of new and innovative tools for clinical and bio-therapeutic applications. This partnership is a great endorsement of the value of Affimer technology in rapid test diagnostics, and I look forward to working together with Mologic and reporting on progress.”

Mark Davis, Chief Executive Officer, Mologic, said: “At Mologic we are continually working to find new ways to improve LFDs. By partnering with Avacta and becoming one of the first companies to develop LFD tests using the Affimer platform, we have the potential to address a wider range of challenging targets than is possible with antibodies alone, with faster development times and improved performance, to the benefit of customers and patients.”
web www.avactaanalytical.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>


White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

Industry Events

Global Bioproduction Summit, 5th-6th February 2018

5-6 February 2018, Hilton San Diego Resort & Spa, CA

After 15 years in Europe, the Global Bioproduction Summit moved to its new home of San Diego in 2016. The Bioproduction Summit delves deep into the world of biological production.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement